← daily scanner dashboard

#1 ANIK — Anika Therapeutics, Inc.

B_VCP_DEVELOPING | as of 2026-09-21 | automated relative priority, not a published Minervini point formula

Relative priority69.29
RS rating94.93
Fundamental strength71.43
VCP score100.00
Pivot distance4.20%
AV confirmation100.00%complete
Technical chart for ANIK

Trend Template

price_above_sma150_and_sma200PASS
sma150_above_sma200PASS
sma200_rising_1mPASS
sma50_above_sma150_and_sma200PASS
price_above_sma50PASS
price_at_least_30pct_above_52w_lowPASS
price_within_25pct_of_52w_highPASS
rs_rating_at_least_70PASS

Trend Template metrics

close20.75
sma5019.46
sma15016.13
sma20014.51
sma200_1m_ago13.26
pct_above_52w_low139.33
pct_below_52w_high9.31
rs_rating94.93

VCP conditions

coherent_contraction_sequencePASS
enough_contractionsPASS
successive_ranges_inside_firstPASS
successive_depths_contractingPASS
final_contraction_tightPASS
base_depth_okPASS
resistance_area_tightPASS
volume_dryupPASS
atr_contractingPASS
price_tightPASS
near_pivotPASS

VCP metrics

num_contractions2.00
contraction_depths_pct[12.02, 6.93]
depth_ratios_vs_prior[0.577]
target_depth_ratio_roughly_half0.50
max_allowed_depth_ratio0.80
base_high22.88
base_low20.13
base_depth_pct12.02
base_duration_weeks6.00
resistance_spread_pct5.33
volume_dryup_ratio_10d_vs_50d0.63
atr_pct_recent3.65
atr_pct_prior5.20
atr_contraction_ratio0.70
tight_10d_range_pct6.05
raw_contraction_count10.00
raw_depths_pct[6.07, 8.93, 25.41, 7.36, 12.6, 5.44, 9.05, 11.58, 12.02, 6.93]
final_trough_age_bars9.00
selection_reasoncoherent_current_sequence
pivot_price21.66
distance_to_pivot_pct4.20
vcp_score_pct100.00
is_vcp_candidatePASS
breakout_on_volumeFAIL

Price / volume

return_1m_pct-2.76
return_3m_pct46.13
return_6m_pct49.82
return_12m_pct132.10
weighted_12m_momentum29.43
range_10d_pct6.05
range_20d_pct11.92
avg_volume_50d98,835
dollar_volume_50d2.05M
up_down_volume_ratio_50d1.33
accumulation_days_20d1.00
distribution_days_20d4.00

Fundamental overlay criteria

eps_growth_minimumPASS
sales_growth_positive_or_betterPASS
core_data_coveragePASS
eps_acceleratingPASS
sales_acceleratingPASS
gross_margin_improvingPASS
operating_margin_improvingPASS

Minervini-oriented SEC fundamentals

eps_growth_yoy_pct185.71
eps_previous_q_yoy_growth_pct-8.82
eps_acceleration_pts194.54
eps_annual_growth_pct80.16
eps_cagr_3y_pct—
sales_growth_yoy_pct15.56
sales_previous_q_yoy_growth_pct13.16
sales_acceleration_pts2.40
sales_annual_growth_pct-5.91
sales_cagr_3y_pct-0.30
gross_margin_pct65.15
operating_margin_pct9.06
pretax_margin_pct10.37
net_margin_pct10.15
gross_margin_yoy_change_pts14.25
operating_margin_yoy_change_pts23.87
roe_latest_fy_pct-7.32
current_ratio4.48
debt_to_equity_pct—
cash_to_debt—
shares_outstanding—
adjusted_eps_growth_yoy_pct—
earnings_surprise_pct—
eps_estimate_revision_30d_pct—
analyst_count—
institutional_ownership_pct—
institutional_qoq_change_pct—
management_guidance_revision_pct—

SEC data quality

core_coverage_pct90.00
missing_core_metrics["shares_outstanding"]
selected_sec_tags{"accounts_payable": "us-gaap:AccountsPayableCurrent", "accounts_receivable": "us-gaap:AccountsReceivableNetCurrent", "capex": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "cash": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "cost_of_revenue": "us-gaap:CostOfGoodsAndServicesSold", "current_assets": "us-gaap:AssetsCurrent", "current_liabilities": "us-gaap:LiabilitiesCurrent", "dividends_paid": null, "eps_basic": "us-gaap:EarningsPerShareBasic", "eps_diluted": "us-gaap:EarningsPerShareDiluted", "equity": "us-gaap:StockholdersEquity", "gross_profit": "us-gaap:GrossProfit", "inventory": "us-gaap:InventoryNet", "long_term_debt": "us-gaap:LongTermDebtNoncurrent", "long_term_debt_current": "us-gaap:LongTermDebtCurrent", "net_income": "us-gaap:NetIncomeLoss", "operating_cash_flow": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "operating_income": "us-gaap:OperatingIncomeLoss", "pretax_income": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "r_and_d": "us-gaap:ResearchAndDevelopmentExpense", "revenue": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "sga": "us-gaap:SellingGeneralAndAdministrativeExpense", "share_repurchases": "us-gaap:PaymentsForRepurchaseOfCommonStock", "shares_outstanding": "dei:EntityCommonStockSharesOutstanding", "short_term_debt": null, "short_term_investments": "us-gaap:MarketableSecuritiesCurrent", "stock_based_comp": "us-gaap:ShareBasedCompensation", "total_assets": "us-gaap:Assets", "total_liabilities": null, "weighted_avg_diluted_shares": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding"}
unavailable_canonical_concepts["dividends_paid", "short_term_debt", "total_liabilities"]
warnings["Standalone Q4 income/EPS can be absent because 10-K statements are annual.", "Company-specific extension tags are not returned by CompanyFacts.", "Non-GAAP EPS, guidance, 13F ownership, Form 4 activity, and analyst estimates are separate modules."]

Reporting periods

latest_quarter_end2026-06-30
latest_quarter_filed2026-07-29
latest_fiscal_year_end2025-12-31
latest_balance_sheet_end2026-06-30

Company metadata

symbolANIK
cik898,437
company_nameAnika Therapeutics, Inc.
exchange—
sic3,841
sic_descriptionSurgical & Medical Instruments & Apparatus
fiscal_year_end1,231
as_of2026-09-21
sourceSEC EDGAR CompanyFacts + Submissions

Alpha Vantage enrichment

latest_reported_date2026-07-29
latest_reported_eps0.30
latest_estimated_eps-0.19
latest_earnings_surprise_pct257.89
avg_earnings_surprise_4q_pct176.40
positive_earnings_surprises_4q4.00
earnings_surprise_quarters_available4.00
estimate_period2027-12-31
analyst_count_eps—
analyst_count_revenue—
eps_estimate_avg—
revenue_estimate_avg—
estimate_revision.eps_estimate_revision_up_trailing_7_days1.00
estimate_revision.eps_estimate_revision_up_trailing_30_days1.00
estimate_revision.eps_estimate_revision_down_trailing_30_days0.00
eps_revision_up_30d1.00
eps_revision_down_30d0.00
eps_revision_net_up_30d1.00
institutional.total_institutional_holders155.00
institutional.total_institutional_shares13.29M
institutional.holders_with_increased_holdings73.00
institutional.holders_with_decreased_holdings55.00
institutional.holders_with_unchanged_holdings27.00
institutional_holder_rows155.00
institutional_total_shares13.29M
endpoints_returned["EARNINGS", "EARNINGS_ESTIMATES", "INSTITUTIONAL_HOLDINGS"]

Alpha Vantage confirmation screen

latest_earnings_surprise_positivePASS
average_4q_earnings_surprise_positivePASS
positive_surprise_quartersPASS
analyst_coverage_present—
eps_revision_breadth_nonnegative_30dPASS
institutional_sponsorship_presentPASS

Alpha Vantage screen summary

statuscomplete
confirmation_score_pct100.00
available_criteria5.00
noteInformational post-Exp0 confirmation only; not part of validated Exp0 selection/ranking.

Alpha Vantage endpoint status

EARNINGScache_available
EARNINGS_ESTIMATEScache_available
INSTITUTIONAL_HOLDINGScache_available

Accepted VCP contractions

peak_datepeak_pricetrough_datetrough_pricedepth_pctdepth_ratio_vs_priorbars
2026-08-1022.882026-08-3120.1312.02—15.00
2026-09-0221.662026-09-0820.166.930.583.00

Recent SEC filings

formfiling_dateaccession_numberprimary_document
10-Q2026-07-290001171843-26-005012anik20260630_10q.htm
8-K2026-07-290001171843-26-004977f8k_072926.htm
8-K2026-07-140001171843-26-004635f8k_071426.htm
8-K2026-06-230001171843-26-004253f8k_062326.htm
10-Q2026-04-300001171843-26-002852anik20260331_10q.htm
8-K2026-04-290001171843-26-002799f8k_042926.htm
10-K2026-03-030001171843-26-001275anik20251231_10k.htm
8-K2026-02-260001193125-26-073401d106406d8k.htm
8-K2026-01-080001193125-26-007655d136217d8k.htm
10-Q2025-11-050001171843-25-007032anik20250930_10q.htm
8-K2025-11-050001171843-25-007003f8k_110525.htm
10-Q2025-07-300001171843-25-004826anik20250630_10q.htm

SEPA factors not covered by SEC + Yahoo

These remain manual or require another provider/module and are deliberately not guessed: